Chris Moertel is currently the Global Head of Clinical Development at Healx and serves as the Clinical Director of Neuro-oncology and Professor of Medicine at the University of Minnesota. With extensive experience in translational oncology research, Chris has held the position of Chief Medical Officer at OX2 Therapeutics since 2017. They have authored multiple INDs and served as Principal Investigator for various phase 1, 2, and 3 clinical trials. Chris has a strong passion for improving the care of individuals living with neurofibromatosis and schwannomatosis, working closely with scientific partners to develop new therapies for these conditions. They earned a Doctor of Medicine degree from the University of Minnesota Medical School between 1980 and 1984.
This person is not in the org chart
This person is not in any teams
This person is not in any offices